Tarsus Pharmaceuticals, Inc. TARS Business Segments — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOther.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — interest income?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — interest income of $3.72M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — interest income changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — interest income increased by 7.8% year-over-year, from $3.45M to $3.72M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — interest income?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — interest income has grown at a 65.1% compound annual growth rate (CAGR), from $3.5M to $15.75M.
- What does business segments — interest income mean?
- Reflects the income generated from cash balances, short-term investments, and other interest-bearing assets held by the company. This provides insight into the company's liquidity management and the return on its capital reserves.